SHP has been associated with resistance to the effects of erythropoietin therapy in patients with CKD-associated anemia; this is defined as failure to normalize hemoglobin after four to six months of erythropoietin therapy in the absence of iron deficiency [51]. This evidence concerns the gene EPO and anemia.